Cabozantinib is primarily used in the treatment of certain types of cancer. It is effective in managing advanced renal cell carcinoma (RCC), a type of kidney cancer, particularly in patients who have previously received anti-angiogenic therapy. The drug is also utilized for treating hepatocellular carcinoma (HCC), a common form of liver cancer, in patients who have been previously treated with sorafenib. Additionally, cabozantinib has shown promise in treating medullary thyroid cancer (MTC) in patients with progressive, metastatic disease. Its mechanism of action involves inhibiting multiple tyrosine kinases, which play a role in tumor growth, angiogenesis, and metastasis, making it a valuable option in targeted cancer therapy.